Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3076
Xenon Pharmaceuticals
XENE
$3.53B
| $269K | ﹤0.01% |
8,600
-146,100
| -94% | -$4.77M |
2023 Q3
7 quarters
|
|
3077
Star Holdings Shares of Beneficial Interest
STHO
$100M
| $269K | ﹤0.01% |
34,399
+2,900
| +9% | +$20K |
2024 Q1
5 quarters
|
|
|
FPAY
3078
DELISTED
FlexShopper
FPAY
| $269K | ﹤0.01% |
223,780
+43,002
| +24% | +$54.6K |
2019 Q1
25 quarters
|
|
|
DHC
3079
Diversified Healthcare Trust
DHC
$1.82B
| $269K | ﹤0.01% |
75,000
+64,300
| +601% | +$186K |
2025 Q1
1 quarter
|
|
3080
Diamondrock Hospitality Co
DRH
$2.58B
| $268K | ﹤0.01% |
+35,000
| New | +$261K |
2025 Q2
0 quarters
|
|
3081
iShares MSCI India Small-Cap ETF
SMIN
$711M
| $266K | ﹤0.01% |
+3,450
| New | +$248K |
2025 Q2
0 quarters
|
|
3082
Janus International
JBI
$570M
| $266K | ﹤0.01% |
+32,700
| New | +$249K |
2025 Q2
0 quarters
|
|
|
WBTN
3083
WEBTOON Entertainment Inc
WBTN
$1.4B
| $264K | ﹤0.01% |
29,066
+14,766
| +103% | +$128K |
2024 Q3
3 quarters
|
|
3084
American Vanguard Corp
AVD
$47.2M
| $262K | ﹤0.01% |
66,752
+40,052
| +150% | +$167K |
2023 Q1
9 quarters
|
|
|
OS
3085
DELISTED
OneStream Inc
OS
| $260K | ﹤0.01% |
+9,200
| New | +$229K |
2025 Q2
0 quarters
|
|
3086
iShares US Consumer Discretionary ETF
IYC
$1.21B
| $259K | ﹤0.01% |
+2,600
| New | +$241K |
2025 Q2
0 quarters
|
|
|
KLRS
3087
Kalaris Therapeutics
KLRS
$56.2M
| $258K | ﹤0.01% |
96,751
+77,500
| +403% | +$350K |
2022 Q1
13 quarters
|
|
3088
Capital Group Core Plus Income ETF
CGCP
$8.36B
| $257K | ﹤0.01% |
+11,400
| New | +$253K |
2025 Q2
0 quarters
|
|
3089
Bridgeline Digital
BLIN
$9.33M
| $256K | ﹤0.01% |
183,829
-14,700
| -7% | -$23.9K |
2020 Q4
18 quarters
|
|
3090
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
$9.64B
| $255K | ﹤0.01% |
+8,600
| New | +$236K |
2025 Q2
0 quarters
|
|
3091
T-Rex 2X Inverse NVIDIA Daily Target ETF
NVDQ
$16.8M
| $255K | ﹤0.01% |
+9,370
| New | +$462K |
2025 Q2
0 quarters
|
|
3092
Imperial Petroleum
IMPP
$247M
| $251K | ﹤0.01% |
81,600
+7,900
| +11% | +$21.7K |
2023 Q4
6 quarters
|
|
3093
Olema Pharmaceuticals
OLMA
$684M
| $250K | ﹤0.01% |
58,800
-5,800
| -9% | -$25.9K |
2024 Q2
4 quarters
|
|
3094
BrightView Holdings
BV
$988M
| $250K | ﹤0.01% |
15,000
-3,800
| -20% | -$56.8K |
2025 Q1
1 quarter
|
|
3095
Nurix Therapeutics
NRIX
$2.32B
| $249K | ﹤0.01% |
21,900
-37,600
| -63% | -$406K |
2025 Q1
1 quarter
|
|
3096
BlackLine
BL
$1.73B
| $249K | ﹤0.01% |
+4,400
| New | +$227K |
2025 Q2
0 quarters
|
|
|
TMHC
3097
DELISTED
Taylor Morrison
TMHC
| $249K | ﹤0.01% |
4,053
-113,300
| -97% | -$6.58M |
2025 Q1
1 quarter
|
|
3098
JPMorgan Active Value ETF
JAVA
$7.06B
| $249K | ﹤0.01% |
+3,800
| New | +$237K |
2025 Q2
0 quarters
|
|
|
BLTE
3099
Belite Bio
BLTE
$6.22B
| $248K | ﹤0.01% |
+4,300
| New | +$262K |
2025 Q2
0 quarters
|
|
3100
Greenwich LifeSciences
GLSI
$243M
| $248K | ﹤0.01% |
27,300
+14,800
| +118% | +$141K |
2022 Q2
12 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.